Beam Therapeutics BEAM Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -226.6%+48.0pp | -274.6%+563pp | -837.1%— | —— | —— | |
| Returns | ||||||
| Return on invested capital | -39.4%+5.5pp | -44.9%+14.4pp | -59.3%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×+0.1× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 17×+3.9× | 13.1×+7.1× | 6×-0.7× | 6.8×-2.1× | 8.8×+4.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.1× | 0.1×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Per Share | ||||||
| Book value per share | $11.28-9.9% | $12.52+32.9% | $9.42-8.2% | $10.26-20.1% | $12.84+44.1% | |
| Valuation | ||||||
| Market capitalization | $2.43B-13.7% | $2.81B+14.6% | $2.46B+42.4% | $1.72B-11.6% | $1.95B-5.0% | |
| Price / sales | 14.8×-5.3× | 20.1×-23.9× | 44.1×+15.5× | 28.6×-2.1× | 30.7×-1.7× | |
| Price / book | 2.1×-0.2× | 2.3×-0.3× | 2.5×+0.9× | 1.6×-0.1× | 1.7×-1.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Beam Therapeutics's ratios come from?
- Every ratio is computed from Beam Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.